Vol 20, No 5 (2024)
Clinical vignette
Published online: 2024-01-31
Trichomegaly as a rare complication of panitumumab therapy for colon cancer
1
, 2, 3, 3, 2
, 2, 3, 3, 2
DOI: 10.5603/ocp.98272
Oncol Clin Pract 2024;20(5):380-381.
Abstract
Not available
Keywords: trichomegalypanitumumabcolon cancerclinical oncologygeneral surgery
References
- Agirgol S, Çaytemel C, Pilanci KN. Dermatological side effects of targeted antineoplastic therapies: a prospective study. Cutan Ocul Toxicol. 2020; 39(4): 380–384.
- Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010; 18(4): 509–522.
- Ragin D, Basałygo M, Nowacka K, et al. Cutaneous adverse reactions during epidermal growth factor receptor inhibitor therapy. Przegl Dermatol. 2018; 105: 421–433.